Bicycle Therapeutics & Oxurion: Positive Topline Phase 1 Results with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of Diabetic Macular Edema (DME)

posted on 01 Jul 2019

Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, today reports positive topline data from a Phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of Diabetic Macular Edema (DME).

THR-149 has been developed in partnership with Bicycle Therapeutics (Nasdaq: BCYC).

The Phase 1 open-label, multicenter (US), non-randomized trial evaluated the safety of a single intravitreal (IVT) injection of THR-149, a novel PKal inhibitor, at 3 ascending dose levels in 12 subjects with visual impairment due to center-involved DME (CI-DME) (NCT03511898).

Topline data from the trial show that THR-149 is well-tolerated and safe. No dose-limiting toxicities nor drug-related serious adverse events were reported at any of the dosages evaluated in the study.

For more details, please see the article here

Copied

Recent posts

PerimeterX Named Overall CyberSecurity Startup of the Year in 2019 CyberSecurity Breakthrough Awards Program

PerimeterX, the leading provider of application security solutions that keep web businesses safe in the complex digital world, today announced that it has been named the winner of the “Overall CyberSecurity Startup of the Year” award in the 2019 CyberSecurity Breakthrough Awards program from CyberSecurity Breakthrough, a leading independent market intelligence organization that recognizes the top companies, technologies and products in the global information security market today.

01 Jul 2019
Read more

Singapore's Vertex adds $290 million venture fund for high-growth tech firms

Vertex Growth Fund achieves a resounding final close of its inaugural fund – Vertex Growth Fund I – at USD290 million. Demand for the fund surpassed the initial target fund size of USD250 million.

01 Jul 2019
Read more

Bicycle Therapeutics & Oxurion: Positive Topline Phase 1 Results with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of Diabetic Macular Edema (DME)

Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, today reports positive topline data from a Phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of Diabetic Macular Edema (DME).

01 Jul 2019
Read more